,10,13 More recent pre-clinical studies suggest that AXL melanoma subpopulations may also be more resistant to immunotherapy, as AXL targeting enhances the response of immune checkpoint blockers in lung cancer, melanoma37 and breast cancer38 models. This evidence concerns the gene AXL and medical procedure.